Alam A S, Imondi A R, Udinsky J, Hagerman L M
Arch Int Pharmacodyn Ther. 1979 Nov;242(1):4-13.
The plasma and urinary concentrations of unchanged 14C-sulpiride were measured in the dog following i.v. and oral administration. Bioavailability of the oral hydrochloride solution was 85% and that of the free base suspension was 75%. Sulpiride equilibrated rapidly with tissue fluid and had an apparent volume of distribution of 3.3--3.8 1/kg. The plasma half-life was 2.5--3 hours. The short plasma half-life and its negligible concentrations in the brain are consistent with the low lipophilicity of supliride. When 100 mg sulpiride was given orally either as hydrochloride or free base, the maximum plasma level was reached within one hour and concentrations were 2.3 and 1.8 micrograms/ml, respectively. The similarity of urinary excretion data from i.v. and oral preparations suggest minimal "first-pass" effect.
静脉注射和口服给药后,在犬体内测定了未代谢的14C-舒必利的血浆和尿液浓度。口服盐酸盐溶液的生物利用度为85%,游离碱混悬液的生物利用度为75%。舒必利与组织液迅速达到平衡,表观分布容积为3.3 - 3.8升/千克。血浆半衰期为2.5 - 3小时。舒必利血浆半衰期短且在脑中浓度可忽略不计,这与其低亲脂性相符。当口服100毫克盐酸盐或游离碱形式的舒必利时,1小时内达到最大血浆浓度,分别为2.3和1.8微克/毫升。静脉注射和口服制剂的尿排泄数据相似,表明“首过”效应极小。